

Nice & Green Renews Commitment to Oryzon Genomics with Up to EUR 45 million in New Funding

Nyon Switzerland, 21 November 2023 – Nice & Green, the Swiss investment firm, announces today a new financing agreement with Oryzon Genomics (ES0167733015 – ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need. The funding of up to EUR 45M will enable Oryzon Genomics to extend its cash runway and continue their ongoing clinical trials in CNS and oncology.

The financing agreement signed between Nice & Green and Oryzon Genomics is materialized via a Horizon Funding Program, a transparent financing tool using Convertible Notes. The conversion price is calculated based on the average VWAP over the selling period of the shares, without any discount. It aims to minimize dilution during the conversion.

The contractual period for this agreement spans 48 months. The initial execution involves EUR 8M, divided into two tranches of EUR 4M each. Optionally, additional tranches of up to EUR 5M each may be executed in the future at Oryzon Genomics's request, subject to customary conditions. This Horizon Funding Program supersedes the previous agreement.

Marc Cattelani, CEO of Nice & Green, commented: "We are pleased to embark on this journey with Oryzon to help strengthen their equity capital and support the advancement of their clinical trials. As a responsible and loyal financial partner, Nice & Green will remain attentive to the evolving financing needs of Oryzon's management team in the near and long term."

Dr. Carlos Buesa, CEO of Oryzon stated: "The current macroeconomic headwinds are a challenge for the stock markets, and the biotechnological sector has been particularly affected. In this unpredictable market situation, we are excited to have secured this financial support from Nice & Green. This funding allows us to strengthen our balance sheet, extend our cash runway, and laser focus on the final execution of PORTICO, our vafidemstat's Phase 2b in borderline personality disorder. We expect PORTICO Topline data in 1Q2024, and if positive, we believe it may be a transformational event for the company. This Financing is relevant in a moment that we plan to start a structured dialogue with industry partners in an indication with multibillion-dollar potential."

About Nice & Green

Nice & Green is a leading privately held Swiss investment firm, active in the European market providing smart funding solutions to listed Micro-, Small- and Mid-Cap companies supporting their growth as partners. Find out more at [nicengreen.ch](https://www.nicengreen.ch).



About Oryzon Genomics

Founded in 2000, Oryzon (BME: ORY) is a clinical stage biopharmaceutical company headquartered in Barcelona, Spain. As the European leader in epigenetics, the company places a strong emphasis on personalized medicine, specifically in the fields of CNS disorders and oncology. Oryzon's dedicated team consists of highly qualified professionals drawn from the pharmaceutical industry, spread across key locations in Barcelona, Boston, NYC, and San Diego.

Oryzon has an advanced clinical portfolio that includes two LSD1 inhibitors: vafidemstat for CNS disorders and iadademstat for oncology. These compounds are currently undergoing Phase II clinical trials. Furthermore, the company is actively developing additional pipeline assets targeting various epigenetic markers. In addition to its drug development efforts, Oryzon maintains a robust platform for biomarker identification and target validation, which supports research in a wide range of malignant and neurological diseases. Find out more at oryzon.com.

Contact Information

Morgane Henchoz
MarCom Specialist

+41 22 361 36 97
mhenchoz@nicengreen.ch

Disclaimer

This press release is provided for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any securities or financial instruments, nor does it constitute investment advice or endorsement of any specific investment opportunity. The information contained in this press release is based on publicly available information and sources believed to be reliable, but no representation or warranty, express or implied, is made as to their accuracy, completeness, or correctness. This press release may contain forward-looking statements, including statements regarding future financial performance, business prospects, and growth strategies. These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied in such statements. The company and its affiliates do not accept any responsibility for any investment decisions made by individuals or entities based on the information provided in this press release. This press release is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. The company reserves the right to amend or update this disclaimer at any time without notice.